Sir Gregory Winter

About

Sir Gregory Winter is a Nobel Laureate and Founding Partner at Ahren Innovation Capital. He is the inventor of the technology leading to Humira (Adalimumab), the first fully human antibody blockbuster drug. He was awarded the 2018 Nobel Prize for his pioneering work in using phage display for the directed evolution of antibodies, with the aim of producing new therapeutics. His development of technologies for making pharmaceutical antibodies by genetic engineering have led to many of the world’s top-selling pharmaceutical treatments for cancer and immune disorders, also including the “humanised” antibodies Herceptin (for treatment of breast cancer) and Lucentis (for treatment of wet acute macular degeneration). He is a founder of three companies and a former Master of Trinity College, University of Cambridge. He sits on the board of Ahren’s portfolio companies Constructive Bio and Bicycle Therapeutics. Sir Gregory was knighted for his services to Molecular Biology in 2004 and his other awards include a Royal Medal in 2011 and the Nobel Prize for Chemistry in 2018. He is a Fellow of the Royal Society.